TNFRSF17 and Miyoshi myopathy: B cell maturation antigen (BCMA) is an effective target for MM due to its highly selective expression in malignant plasma cells (PCs), which shows effective clinical response in patients with relapsed and refractory MM with the treatment of BCMA antibodies as well as its related chimeric antigen receptor (CAR)-T cells.